Categories Analysis, Health Care, U.S. Markets News

European competition threatens AbbVie’s run of top-selling Humira

US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to compete in Europe.

Chief Executive Officer Richard Gonzalez, in a conference call, said, “we’ve seen discounting at ranges from as low as 10 percent to as high as around 80 percent.”

European competition threatens AbbVie's run of top-selling Humira
AbbVie scientist looks at experimental results through a microscope. (Courtesy: AbbVie)

According to AbbVie chief, Nordic countries saw the highest cut, especially in a time when the market thinks cheaper biosimilar competition will continue to be strong in the coming year in the continent as well.

Analysts expect the competition to adversely affect, and gain more momentum in 2020, with Mylan NV (MYL), Biogen Inc (BIIB) Amgen Inc (AMGN) and Novartis AG (NOVN) all starting the sales of biosimilar versions of Humira in Europe. this has caused quite a bit of unrest amongst investors, especially when the blockbuster prescription medicine brings in about two-thirds of AbbVie’s top line.

AbbVie third quarter 2018 Earnings Infographic

In the US, however, AbbVie is safe, since biosimilar competition is not expected until 2023. Outside the US, the medical giant sees a 26-27% drop in Humira sales next year, more than the earlier expected 18-20% slip.

In the last reported quarter, total Humira sales were 9% higher at $5.12 billion. Apart from it, leukemia drug Imbruvica also exhibited higher-than-expected sales in the period, hitting $972 million — much higher than the analyst consensus of $885.6 million. Maybe, these strong fundamentals could be the reason for the stock not reacting much to the CEO comments, as it remained flat at $79.77 following the outlook.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top